Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8638559 | 0.82 | HPGD (0.65) | HTTALDH1A1HPGDACLYKMT2A | |
| SCHEMBL18741163 | 0.82 | HPGD (0.66) | HTTROCK2ROCK1ALDH1A1HPGD | |
| SCHEMBL18741302 | 0.82 | ROCK2 (0.64) | ROCK2ROCK1HPGDKMT2A | |
| SCHEMBL4879445 | 0.81 | ROCK2 (0.60) | ROCK2ROCK1HPGD | |
| SCHEMBL17443355 | 0.77 | NPC1 (0.48) | HTTROCK2ROCK1ALDH1A1KMT2A | |
| SCHEMBL12700344 | 0.77 | HTT (0.76) | HTTALDH1A1HPGDKMT2AAPEX1 | |
| SCHEMBL31023451 | 0.76 | EPHX2 (0.62) | ROCK2ROCK1 | |
| SCHEMBL18741148 | 0.76 | SCN2A (0.52) | ROCK2ROCK1 | |
| SCHEMBL28350597 | 0.75 | MEN1 (0.60) | HTTALDH1A1HPGDKMT2A | |
| SCHEMBL27726847 | 0.75 | HPGD (0.53) | HTTTYMSALDH1A1HPGDACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | claimed |
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | ADORA2A, ADORA1, ADORA3 | HTT 4387/4885CYP4F2 493/4885CYP4A11 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.